RT Journal Article
SR Electronic
T1 Are COVID-19 proximity tracing apps working under real-world conditions? Indicator development and assessment of drivers for app (non-)use
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.29.20184382
DO 10.1101/2020.08.29.20184382
A1 Viktor von Wyl
A1 Marc Höglinger
A1 Chloé Sieber
A1 Marco Kaufmann
A1 André Moser
A1 Miquel Serra-Burriel
A1 Tala Ballouz
A1 Dominik Menges
A1 Anja Frei
A1 Milo A. Puhan
YR 2020
UL http://medrxiv.org/content/early/2020/09/02/2020.08.29.20184382.abstract
AB Digital proximity tracing (DPT) apps have been released to mitigate SARS-CoV-2 transmission, but it remains unclear how their effectiveness should be monitored. The aim of this study was to formalize indicators for measuring the fulfillment of assumptions for appropriate proximity tracing app functioning.Six indicators were developed to monitor the SwissCovid app functioning and effectiveness in the Swiss population. Using official statistics and survey data, we calculated indicator values and examined socio-demographic factors associated with the SwissCovid app utilization. Indicators show that 1 in 3 adults in Switzerland have downloaded the app. However, only 15% of new cases also triggered DPT-app notifications, and indicators also reveal ignored app notifications. In the full survey sample (n=2’098), higher monthly household income or being a non-smoker were associated with higher SwissCovid app uptake; older age or having a non-Swiss nationality with a lower uptake. In a subsample including more detailed information (n=701), high trust in health authorities was associated with higher SwissCovid app uptake.The indicators help to monitor key drivers of DPT-apps effectiveness and hint to non-compliance issues. Streamlining procedures, removing technical hurdles, and communicating the usefulness of DPT-apps are crucial to promote uptake, compliance, and ultimately effectiveness of DPT-apps for pandemic mitigation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Corona Immunitas study has received funding from the Federal office of Public Health, the Swiss Schools of Public Health (SSPH+) Foundation, the University of Zurich Foundation, and the University of Zurich. The Social Monitor study has received funding from the Federal Office of Public Health and from Health Promotion Switzerland. The Funders have no influence on the design, conduct, analyses and publications. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Corona Immunitas Zurich study was approved by the Ethics Committee of the Canton Zurich (BASEC-Nr. 2020-01247), and informed consent was obtained from all participants. For the Covid-19 Social Monitor, the Ethics Committee of the Canton Zurich confirmed that it does not fall under the Swiss Human Research Law (BASEC-Nr. Req-2020-00323). Therefore, informed consent was not needed. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.